Literature DB >> 18976920

Restriction of retroviral replication by APOBEC3G/F and TRIM5alpha.

Hendrik Huthoff1, Greg J Towers.   

Abstract

Pathogenic viral infections have exerted selection pressure on their hosts to evolve cellular antiviral inhibitors referred to as restriction factors. Examples of such molecules are APOBEC3G, APOBEC3F and TRIM5alpha. APOBEC3G and APOBEC3F are cytidine deaminases that are able to strongly inhibit retroviral replication by at least two mechanisms. They are counteracted by the lentiviral Vif protein. TRIM5alpha binds to sensitive, incoming retroviruses via its C-terminal PRY/SPRY domain and rapidly recruits them to the proteasome before significant viral DNA synthesis can occur. Both of these proteins robustly block retroviral replication in a species-specific way. It remains an open but important question as to whether innate restriction factors such as these can be harnessed to inhibit HIV-1 replication in humans.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18976920      PMCID: PMC3556578          DOI: 10.1016/j.tim.2008.08.013

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN: 0966-842X            Impact factor:   17.079


  79 in total

1.  Retroviral restriction factors Fv1 and TRIM5alpha act independently and can compete for incoming virus before reverse transcription.

Authors:  Luca D Passerini; Zuzana Keckesova; Greg J Towers
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

2.  Cyclophilin A renders human immunodeficiency virus type 1 sensitive to Old World monkey but not human TRIM5 alpha antiviral activity.

Authors:  Zuzana Keckesova; Laura M J Ylinen; Greg J Towers
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

3.  Rhesus monkey TRIM5alpha restricts HIV-1 production through rapid degradation of viral Gag polyproteins.

Authors:  Ryuta Sakuma; Josh A Noser; Seiga Ohmine; Yasuhiro Ikeda
Journal:  Nat Med       Date:  2007-04-15       Impact factor: 53.440

4.  Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.

Authors:  Stuart J D Neil; Trinity Zang; Paul D Bieniasz
Journal:  Nature       Date:  2008-01-16       Impact factor: 49.962

5.  Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species.

Authors:  Cesar A Virgen; Zerina Kratovac; Paul D Bieniasz; Theodora Hatziioannou
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

6.  Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1.

Authors:  Eri Miyagi; Sandrine Opi; Hiroaki Takeuchi; Mohammad Khan; Ritu Goila-Gaur; Sandra Kao; Klaus Strebel
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

7.  Cytidine deamination induced HIV-1 drug resistance.

Authors:  Lubbertus C F Mulder; Ariana Harari; Viviana Simon
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-07       Impact factor: 11.205

8.  The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys.

Authors:  Matthew Stremlau; Christopher M Owens; Michel J Perron; Michael Kiessling; Patrick Autissier; Joseph Sodroski
Journal:  Nature       Date:  2004-02-26       Impact factor: 49.962

9.  Dual inhibitory effects of APOBEC family proteins on retrotransposition of mammalian endogenous retroviruses.

Authors:  Cécile Esnault; Jean Millet; Olivier Schwartz; Thierry Heidmann
Journal:  Nucleic Acids Res       Date:  2006-03-14       Impact factor: 16.971

10.  Evolution of a TRIM5-CypA splice isoform in old world monkeys.

Authors:  Ruchi M Newman; Laura Hall; Andrea Kirmaier; Lu-Ann Pozzi; Erez Pery; Michael Farzan; Shawn P O'Neil; Welkin Johnson
Journal:  PLoS Pathog       Date:  2008-02-29       Impact factor: 6.823

View more
  51 in total

Review 1.  Features, processing states, and heterologous protein interactions in the modulation of the retroviral nucleocapsid protein function.

Authors:  Gilles Mirambeau; Sébastien Lyonnais; Robert J Gorelick
Journal:  RNA Biol       Date:  2010-11-01       Impact factor: 4.652

2.  Retroviral restriction factors and infectious risk in xenotransplantation.

Authors:  Y Meije; R R Tönjes; J A Fishman
Journal:  Am J Transplant       Date:  2010-07       Impact factor: 8.086

3.  Hexagonal assembly of a restricting TRIM5alpha protein.

Authors:  Barbie K Ganser-Pornillos; Viswanathan Chandrasekaran; Owen Pornillos; Joseph G Sodroski; Wesley I Sundquist; Mark Yeager
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

Review 4.  Studies of endogenous retroviruses reveal a continuing evolutionary saga.

Authors:  Jonathan P Stoye
Journal:  Nat Rev Microbiol       Date:  2012-05-08       Impact factor: 60.633

Review 5.  The evolutionary conundrum of pathogen mimicry.

Authors:  Nels C Elde; Harmit S Malik
Journal:  Nat Rev Microbiol       Date:  2009-10-06       Impact factor: 60.633

Review 6.  Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs.

Authors:  Mayte Coiras; María Rosa López-Huertas; Mayte Pérez-Olmeda; José Alcamí
Journal:  Nat Rev Microbiol       Date:  2009-11       Impact factor: 60.633

Review 7.  Retroviral restriction and dependency factors in primates and carnivores.

Authors:  Hind J Fadel; Eric M Poeschla
Journal:  Vet Immunol Immunopathol       Date:  2011-06-12       Impact factor: 2.046

Review 8.  The macrophage in HIV-1 infection: from activation to deactivation?

Authors:  Georges Herbein; Audrey Varin
Journal:  Retrovirology       Date:  2010-04-09       Impact factor: 4.602

9.  Variability in a dominant block to SIV early reverse transcription in rhesus monkey cells predicts in vivo viral replication and time to death.

Authors:  Thomas F Rogers; So-Yon Lim; T J Sundsvold; Tiffany Chan; Ariel Hsu; Norman L Letvin
Journal:  Virol J       Date:  2010-04-26       Impact factor: 4.099

10.  BCA2/Rabring7 promotes tetherin-dependent HIV-1 restriction.

Authors:  Kei Miyakawa; Akihide Ryo; Tsutomu Murakami; Kenji Ohba; Shoji Yamaoka; Mitsunori Fukuda; John Guatelli; Naoki Yamamoto
Journal:  PLoS Pathog       Date:  2009-12-18       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.